Companies Investors People

Drop to look up

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing
Alternatives

For iPhone and iPad

Resources

Documentation
Use Cases
CLI
MCP
Sitemap

aVenture is an AI-native agentic deep research tool for researching and finding companies and people, and is a high-quality alternative to AlphaSense, CB Insights, Crunchbase, Dealroom, Harmonic, Owler, Perplexity Finance, PitchBook, Preqin, PrivCo, Synaptic, and Tracxn.

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Terms of service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Sweet Chemistry

Sweet Chemistry

Part of Xylyx Bio

Sweet Chemistry's regenerative skincare uses Matrikynes, a technology built on extracellular-matrix polypeptides developed for organ repair.

: Company
: 2023
: New York, NY, USUnited States

Sweet Chemistry is a research-driven skincare brand founded by scientists at regenerative-medicine company Xylyx Bio to fund Xylyx Bio’s research; Xylyx Bio is its parent and research-and-development liaison. It formulates with extracellular-matrix polypeptides developed for organ repair.

Sweet Chemistry’s formulas are powered by Matrikynes, a technology built on extracellular-matrix polypeptides developed for organ repair. Matrikynes has been used in clinical applications to heal damaged organs and is now verified by independent clinical testing for skin tissue renewal.

Similar Companies

Xylyx Bio

Repairogen

repairogen.com

Mother Science

motherscience.com

Ktchn Apothecary

Michal Morrison

michalmorrison.com

Experiment

Pollynation Apothecary

Mxt

mxt.co

True & Co

trueandco.com

Bluelene

bluelene.com

Element Eight

elementeight.com

K&K Skin Products

kkskinproducts.com

Soteri Skin

soteriskin.com

Nerd Skincare

nerdskincare.com

Melliderm

Seaspire Skincare

Dermarus

Truly O2

trulyo2.com

Chrysallis

chrysallis.com

RegenX Science

regenxscience.com

Sciote Skin

Quick Facts

Who are Sweet Chemistry's competitors?

Companies similar to Sweet Chemistry include Repairogen, Mother Science, Ktchn Apothecary and Michal Morrison.

When was Sweet Chemistry founded?

Sweet Chemistry was founded in 2023.

Where is Sweet Chemistry's headquarters located?

Sweet Chemistry's headquarters is located in New York, NY, US.

When was Sweet Chemistry's last funding round?

Sweet Chemistry's most recent funding round was for $1.5M (USD) in April 2026.

How much disclosed funding has Sweet Chemistry raised?

As of Apr 12, 2026, Sweet Chemistry has disclosed funding of $1.5M (USD). Undisclosed round amounts are excluded.

Classification

Industry: Consumer Products
Technology: Shopify
Geographic Exposure: United States

Model: Consumer Products
Direct To Consumer
Revenue: E-commerce
Product Sales
Customer: B2C
Consumer

Tags: Consumer
Skincare